Filing Details
- Accession Number:
- 0001127602-13-032206
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-11-19 16:53:01
- Reporting Period:
- 2013-11-15
- Filing Date:
- 2013-11-19
- Accepted Time:
- 2013-11-19 16:53:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1145197 | Insulet Corp | PODD | Surgical & Medical Instruments & Apparatus (3841) | 043523891 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1259094 | K Brian Roberts | C/O Insulet Corporation 9 Oak Park Drive Bedford MA 01730 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-11-15 | 20,000 | $5.11 | 119,216 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-11-15 | 7,500 | $35.25 | 111,716 | No | 4 | S | Direct | |
Common Stock | Disposition | 2013-11-15 | 8,500 | $36.41 | 103,216 | No | 4 | S | Direct | |
Common Stock | Disposition | 2013-11-15 | 4,000 | $36.87 | 99,216 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2013-11-15 | 20,000 | $0.00 | 20,000 | $5.11 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
50,000 | 2019-03-05 | No | 4 | M | Direct |
Footnotes
- Includes 8,000 restricted stock units granted on March 1, 2011 which vest on March 1, 2014; 3,750 restricted stock units granted on March 1, 2011 which vest on December 31, 2013; 18,750 restricted stock units granted on April 1, 2012 which vest one-third of the total units on April 1, 2014, one-third of the total units on April 1, 2015 and one-third of the total units on April 1, 2016; and 30,000 restricted stock units granted on March 1, 2013 which vest one-quarter of the total units on March 1, 2014, one-quarter of the total units on March 1, 2015, one-quarter of the total units on March 1, 2016 and one-quarter of the total units on March 1, 2017. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2013.
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $34.75 to $35.75. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $35.77 to $36.77. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $36.775 to $37.12. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.